1800 Williams St., Suite 200 • Denver, CO 80218
Phone 303-388-4876 • Fax 303-336-2193 • Toll Free 1-800-891-7622

URL http://www.rockymountainbmt.com/news/Multiple-myeloma-patients-associated-with-risk-of-osteonecrosis-of-the-jaw-605.html

Multiple myeloma patients associated with risk of osteonecrosis of the jaw

06-20-2006

Multiple myeloma (MM) patients could be at risk for developing osteonecrosis of the jaw (ONJ).

According to a recent report, researchers in the United States conducted a study "to describe the clinical, radiologic, and pathologic features and risk factors for ONJ in MM patients. A retrospective review of 90 MM patients who had dental assessments, including 22 patients with ONJ. There were 62 men; the median age was 61 years in ONJ patients and 58 years among the rest."

"Prior MM therapy included thalidomide (n=67) and stem-cell transplantation (n=72). Bisphosphonate therapy included zoledronate (n=34) or pamidronate (n=17) and pamidronate followed by zoledronate (n=33). Twenty-seven patients had recent dental extraction, including 12 patients in the ONJ group. Median time from MM diagnosis to ONJ was 8.4 years for the whole group. Patients usually presented with pain. ONJ occurred posterior to the cuspids (n=20) mostly in the mandible. Debridement and sequestrectomy with primary closure were performed in 14 patients; of these, 4 patients had major infections and 4 patients had recurrent ONJ.

"Bone histology revealed necrosis and osteomyelitis. Microbiology showed actinomycetes (n=7) and mixed bacteria (n=9). More than a third of ONJ patients also suffered from long bone fractures (n=4) and/or avascular necrosis of the hip (n=4). The variables predictive of developing ONJ were dental extraction (p=.009), treatment with pamidronate/zoledronate (p=.009), longer follow-up time (p=.03), and older age at diagnosis of MM (p=.006)," explained A. Badros and colleagues, University of Maryland.

The researchers concluded, "ONJ appears to be time-dependent with higher risk after long-term use of bisphosphonates in older MM patients often after dental extractions. No satisfactory therapy is currently available. Trials addressing the benefits/risks of continuing bisphosphonate therapy are needed."

Badros and colleagues published their study in the Journal of Clinical Oncology (Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol, 2006;24(6):945-952).

For additional information, contact A. Badros, University of Maryland, Marlene & Stewart Greenebaum Cancer Center, 22 S Greene St., Baltimore, MD 21201, USA.

Publisher contact information for the Journal of Clinical Oncology is: American Society Clinical Oncology, 330 John Carlyle St., Ste. 300, Alexandria, VA 22314, USA.

Keywords: Baltimore, Maryland, United States, Actinomycete, Bacteriology, Disease Association, Cell Transplant, Dental Health, Dentistry, Multiple Myeloma, Oncology, Oral Health, Osteomyelitis, Risk Factor, Thalidomide, Cancer Therapy, Jaw, Osteonecrosis.

This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2006, Clinical Oncology Week via NewsRx.com.